Helix BioPharma Corp. Announces Fiscal First Quarter 2019 Results
December 14, 2018 17:34 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer,...
Helix Biopharma Corp. Closes First Tranche of Private Placement
December 06, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
Helix BioPharma Corp. Provides Strategic Update on L-DOS47 Clinical Program
November 13, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer,...
Helix BioPharma Corp. to initiate new L-DOS47 clinical program in pancreatic cancer
November 01, 2018 07:30 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates...
Helix BioPharma Corp. Closes Private Placement
October 30, 2018 17:05 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
Helix BioPharma Corp. Announces Fiscal 2018 Year-End Results
October 26, 2018 17:25 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer,...
Helix BioPharma Corp. Extends Period to Exercise Warrants
October 16, 2018 18:03 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the...
Helix BioPharma Corp. and Moffitt Cancer Center extend collaboration on immunotherapy, including study of L-DOS47 with PD-1/PD-L1 inhibitors
October 10, 2018 07:30 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates...
Helix BioPharma Corp. Initiates Enrollment of the Second Last Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47
September 13, 2018 07:30 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the...
Helix BioPharma Corp. collaborator ProMab Biotechnologies Publishes Paper on Multiple Myeloma CAR-T
September 12, 2018 07:30 ET
|
Helix BioPharma Corp.
RICHMOND HILL, Ontario, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP), (FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for...